Wei Zhao introduces CRISPR idea for flu at symposium

At October's Pandemic Research Alliance Symposium, researcher Wei Zhao presented an innovative concept using CRISPR to combat influenza. The idea targets the virus's replication process, potentially halting its spread. This development highlights ongoing efforts in gene-editing research against relentless flu strains.

In a presentation to virologists from China, Australia, and Singapore, Wei Zhao shared an eye-catching idea at the Pandemic Research Alliance Symposium held in October. The concept leverages CRISPR, a powerful gene-editing tool, to address the influenza virus's ability to replicate within cells. As detailed in a WIRED article published on January 5, 2026, this innovative research aims to stop the flu in its tracks by interfering with viral mechanisms.

The symposium brought together experts to discuss pandemic preparedness, and Zhao's introduction underscores the potential of genetic interventions in virology. Keywords associated with the research include genetics, health, flu, CRISPR, research, cells, and viruses. While specifics of the idea remain introductory, it points to promising advancements in antiviral strategies against a disease that affects millions annually.

This development occurs amid global interest in tools like CRISPR for treating infectious diseases. The article emphasizes the relentless nature of influenza and the hope that such targeted approaches could enhance future defenses.

Related Articles

Scientific illustration of bird flu virus PB1 gene enabling replication at fever temperatures, contrasting with human flu, highlighting pandemic concerns.
Image generated by AI

Key flu gene helps bird viruses withstand fever temperatures, study finds

Reported by AI Image generated by AI Fact checked

Scientists from the universities of Cambridge and Glasgow have shown why many bird flu viruses can keep replicating at fever-like temperatures that typically curb human flu. A study in Science identifies the viral PB1 gene as crucial to this heat tolerance, raising concerns about pandemic risks if such genes move into human strains.

An international team led by ETH Zurich and including researchers in Japan has used a new high‑resolution imaging technique to watch, live, as influenza viruses penetrate human cells. The work shows that cells actively engage with the virus, helping to draw it inside in a process that resembles surfing along the cell membrane, and could inform the development of targeted antiviral therapies.

Reported by AI

A nasal spray delivering a broad-spectrum antibody has demonstrated potential to prevent infections from any flu strain in animal and preliminary human studies. Developed initially by Johnson & Johnson and now advanced by Leyden Labs, the spray could offer rapid protection during pandemics. Experts see it as a valuable tool for high-risk groups, though further testing is needed.

Researchers from New England Biolabs and Yale University have developed the first fully synthetic system for engineering bacteriophages targeting Pseudomonas aeruginosa, a major antibiotic-resistant bacterium. Published in PNAS, the method uses digital DNA sequences to build viruses from scratch, bypassing traditional challenges in phage modification. This innovation aims to accelerate therapies against global antibiotic resistance threats.

Reported by AI Fact checked

Scientists at Virginia Tech report that tuning specific molecular pathways with CRISPR-based tools improved memory in older rats across two peer‑reviewed studies, pointing to possible routes for tackling age‑related cognitive decline.

US-based Insilico Medicine, backed by Fosun and Tencent, is expanding its research base in China to develop an AI-powered drug-discovery tool called Pharma.AI. Founder Alex Zhavoronkov likened the tool to an “Einstein” capable of advancing drug discovery into new frontiers.

Reported by AI

Health Minister Ximena Aguilera presented to the Chamber of Deputies measures to tackle the H3N2 influenza threat, dubbed supergripe, after cases were confirmed in Peru. The government plans to advance the vaccination campaign to safeguard vulnerable groups and prevent overloads in the health system. Officials emphasize preparation drawing from past experiences like Covid-19.

 

 

 

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline